IPR2022-00056 - Biofrontera Pharma GMBH et al. v. Bell Northern Research LLC et al.Report Error
Details
PATENT NUMBER
APPL. NUMBER
15869164
PETITIONER
STATUS
Settlement
FILING DATE
2021-10-19
INSTITUTION DATE
N/A
TERMINATION DATE
2022-01-24
AUTHOR JUDGE
Timeline
Petition
Notice of Filing Date
Motion to Terminate
Motion to Terminate
Final Decision
Oct
Nov
Dec
2022
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2023
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2024
Feb
Mar
Docket
| 1 | 2021-10-19 | Petitioner | Petition | Petition for Inter Partes Review Under 35 U.S.C. 312 |
| 2 | 2021-10-19 | Petitioner | Power of Attorney | Petitioner's Power of Attorney |
| 1001 | 2021-10-19 | Petitioner | U.S. Patent No. 10,357,567 | |
| 1002 | 2021-10-19 | Petitioner | Excerpts from U.S. Patent Application No. 15/869,164 | |
| 1003 | 2021-10-19 | Petitioner | Declaration of Dr. Howard Rogers MD, PHD | |
| 1004 | 2021-10-19 | Petitioner | CV of Dr. Howard Rogers MD, PHD | |
| 1005 | 2021-10-19 | Petitioner | PCT Publication No. WO 96/06602 (Noven Pharma) | |
| 1006 | 2021-10-19 | Petitioner | Sakamoto FH, Torezan L, Anderson RR. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol. 2010 Aug;63(2):195-211 | |
| 1007 | 2021-10-19 | Petitioner | Berardesca E, Vignoli GP, Fideli D, Maibach H. Effect of occlusive dressings on the stratum corneum water holding capacity. The American Journal of the Medical Sciences. 1992 Jul;304(1):25-28 | |
| 1008 | 2021-10-19 | Petitioner | Fauteck JD, Ackermann G, Birkel M, Breuer M, Moor AC, Ebeling A, Ortland C. Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses. | |
| 1009 | 2021-10-19 | Petitioner | U.S. Patent Publication No. US2009/0324727 A1 (Biofrontera) | |
| 1010 | 2021-10-19 | Petitioner | Ameluz�� Prescribing Information (2016) | |
| 1011 | 2021-10-19 | Petitioner | Levulan�� Label (2002) | |
| 1012 | 2021-10-19 | Petitioner | Blu-U�� Operating Manual (2006) | |
| 1013 | 2021-10-19 | Petitioner | Willey A, Anderson RR, Sakamoto FH. Temperature-modulated photodynamic therapy for the treatment of actinic keratosis on the extremities. Dermatologic Surgery. 2014 Oct;40(10):1094- 1102 | |
| 1014 | 2021-10-19 | Petitioner | Calderhead RG. Light-emitting diode phototherapy in dermatological practice in lasers in dermatology and medicine. Lasers in Dermatology and Medicine. 2011 Aug:231-265 | |
| 1015 | 2021-10-19 | Petitioner | Palm M., Goldman PM. Aminolevulinic acid: actinic keratosis and photorejuvenation. In: Gold M.H., editor. Photodynamic Therapy in Dermatology. Springer Science and Business Media, LLC. 2011 Nov:5-30 | |
| 1016 | 2021-10-19 | Petitioner | MacCormack MA. Photodynamic therapy in dermatology: an update on applications and outcomes. Semin Cutan Med Surg. 2008 Mar;27(1):52-62 | |
| 1017 | 2021-10-19 | Petitioner | Sotiriou E, Apalla Z, Maliamani F, Zaparas N, Panagiotidou D, Ioannides D. Intraindividual, right-left comparison of topical 5- aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. | |
| 1018 | 2021-10-19 | Petitioner | Bissonnette R. Photodynamic therapy. In: Gold M.H., editor. Photodynamic Therapy in Dermatology. Springer Science and Business Media, LLC; New York, NY, USA: 2011. pp. 221���229 | |
| 1019 | 2021-10-19 | Petitioner | McLaren G. Photodynamic therapy. In; Pfenninger and Fowler's procedures for primary care. Third Ed. Mosby Elsevier; Philadelphia, PA: 2011. pp 397-400 | |
| 1020 | 2021-10-19 | Petitioner | Harris DR. Percutaneous absorption and the surface area of occluded skin: a scanning electron microscopic study. British Journal of Dermatology. 1974; 91(27-32) | |
| 1021 | 2021-10-19 | Petitioner | Levulan�� Label (2009) | |
| 1022 | 2021-10-19 | Petitioner | Wachowska et al., Aminolevulinic acid (ALA) as a prodrug in photodynamic therapy of cancer. Molecules. 2011 May; 16(5): 4140-4164 | |
| 1023 | 2021-10-19 | Petitioner | Agostinis et al. Photodynamic therapy of cancer: an update. CA: A Cancer Journal for Clinicians. 2011 May; 61(4):250-2 | |
| 1024 | 2021-10-19 | Petitioner | Wolf P., Rieger E. and Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5- aminolevulinic acid: an alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? | |
| 1025 | 2021-10-19 | Petitioner | Jeffes E., McCullough J., Weinstein G., Fergin P., Nelson J., Shull T., Simpson K., Bukaty L., Hoffman W., Fong N. Photodynamic therapy of actinic keratosis with topical 5- aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol. 1997 | |
| 1026 | 2021-10-19 | Petitioner | Hongcharu W., Taylor C., Chang, Y., Aghasi, D., Suthamjariya, K., Anderson, R. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol. 2000 Aug;115(2):183-92 | |
| 1027 | 2021-10-19 | Petitioner | Ozog, D., Rkein, A., Fabi, S., Gold M., Goldman, M., Lowe, N., Martin, G., Munavalli, G. Photodynamic therapy: A clinical consensus guide. Dermatol Surg. 2016 Jul;42(7):804-27 | |
| 1028 | 2021-10-19 | Petitioner | Aktilite CL128 Operators Manual with Metvixia | |
| 1029 | 2021-10-19 | Petitioner | DUSA Levulan Press Release | |
| 1030 | 2021-10-19 | Petitioner | European Medicines Agency CHMP Assessment Report (excerpts) | |
| 1031 | 2021-10-19 | Petitioner | Affidavit of Duncan Hall | |
| 1032 | 2021-10-19 | Petitioner | Willey Pubmed Website Database Listing | |
| 1033 | 2021-10-19 | Petitioner | Sotiriou Pubmed Website Database Listing | |
| 1034 | 2021-10-19 | Petitioner | Fauteck Europe PMC Website Database Listing | |
| 1035 | 2021-10-19 | Petitioner | Rick K, Sroka R, Stepp H, Kriegmair M, Huber RM, Jacob K, Baumgartner R. Pharmacokinetics of 5-aminolevulinic acidinduced protoporphyrin IX in skin and blood. J Photochem Photobiol B. 1997 Oct;40(3):313-9 | |
| 1036 | 2021-10-19 | Petitioner | International Patent Reviews, LLC review of U.S. Patent No. 10,357,567 dated July 26, 2021 | |
| 1037 | 2021-10-19 | Petitioner | News article entitled DUSA Pharmaceuticals To Pay U.S. $20.75 Million To Settle False Claims Act Allegations Relating To Promotion Of Unsupported Drug Administration Process | |
| 3 | 2021-10-29 | Board | Notice of Filing Date | Notice: Notice filing date accorded |
| 4 | 2021-11-09 | Potential Patent Owner | Mandatory Notice | Patent Owner's Mandatory Notices |
| 5 | 2021-11-09 | Potential Patent Owner | Power of Attorney | Patent Owner's Power of Attorney |
| 6 | 2021-12-03 | Petitioner | Motion to Terminate | Unopposed Motion to Dismiss Petition for Inter Partes Review |
| 7 | 2021-12-28 | Board | Other | Denying, without Prejudice, Petitioner Motion to Dismiss the Petition 37 C.F.R. §§ 42.5(a), 42.71(a), 42.74(b) |
| 8 | 2022-01-18 | Petitioner | Motion to Terminate | Renewed Unopposed Motion to Dismiss Petition for Inter Partes Review |
| 9 | 2022-01-18 | Petitioner | Other | Joint Request that Settlement Agreement Be Treated as Business Confidential Information and Be Kept Separate Pursuant to 35 U.S.C. �� 317(b) and 37 C.F.R. �� 42.74(c) |
| 10 | 2022-01-24 | Board | Final Decision | Termination Decision: Pre-DI dismissal |
| 11 | 2022-01-28 | Petitioner | Other | Request for Refund of Post-Institution Fees |
| 12 | 2022-01-31 | Board | Other | Notice: refund approved |
Grounds Asserted